Lexaria Bioscience Corp Stock Performance
| LEXXW Stock | USD 0.36 0.00 0.000003% |
The company secures a Beta (Market Risk) of 1.11, which conveys a somewhat significant risk relative to the market. Lexaria Bioscience returns are very sensitive to returns on the market. As the market goes up or down, Lexaria Bioscience is expected to follow. At this point, Lexaria Bioscience Corp has a negative expected return of -0.42%. Please make sure to verify Lexaria Bioscience's accumulation distribution, as well as the relationship between the day typical price and relative strength index , to decide if Lexaria Bioscience Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Lexaria Bioscience Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | Lexaria Forms New Scientific Advisory Board | 12/18/2024 |
2 | Acquisition by Baxter Nicholas W of 110000 shares of Lexaria Bioscience at 0.1 subject to Rule 16b-3 | 01/03/2025 |
3 | Acquisition by Baxter Nicholas W of 5000 shares of Lexaria Bioscience at 7.08 subject to Rule 16b-3 | 01/08/2025 |
4 | Lexarias Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lillys Injectable GLP-1GIP Drug Zepbound | 01/14/2025 |
5 | Disposition of 50000 shares by Spissinger Allan Horst of Lexaria Bioscience at 0.37 subject to Rule 16b-3 | 01/17/2025 |
6 | Lexaria Bioscience stock target cut to 7 at H.C. Wainwright - Investing.com | 01/24/2025 |
7 | Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy | 02/11/2025 |
8 | Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector - TipRanks | 02/27/2025 |
9 | Acquisition by Spissinger Allan Horst of 650000 shares of Lexaria Bioscience at 0.32 subject to Rule 16b-3 | 03/07/2025 |
10 | Lexarias DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lillys Injectable Zepbound | 03/18/2025 |
| Begin Period Cash Flow | 1.4 M |
Lexaria |
Lexaria Bioscience Relative Risk vs. Return Landscape
If you would invest 80.00 in Lexaria Bioscience Corp on December 24, 2024 and sell it today you would lose (44.00) from holding Lexaria Bioscience Corp or give up 55.0% of portfolio value over 90 days. Lexaria Bioscience Corp is currently producing negative expected returns and takes up 14.2306% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Lexaria, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Lexaria Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lexaria Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lexaria Bioscience Corp, and traders can use it to determine the average amount a Lexaria Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0294
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LEXXW |
Estimated Market Risk
| 14.23 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lexaria Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lexaria Bioscience by adding Lexaria Bioscience to a well-diversified portfolio.
Lexaria Bioscience Fundamentals Growth
Lexaria Stock prices reflect investors' perceptions of the future prospects and financial health of Lexaria Bioscience, and Lexaria Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lexaria Stock performance.
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.67 | ||||
| Operating Margin | (14.63) % | ||||
| Revenue | 464.28 K | ||||
| Gross Profit | 494.2 K | ||||
| EBITDA | (5.68 M) | ||||
| Net Income | (5.81 M) | ||||
| Cash And Equivalents | 1.31 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 137.37 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 8.52 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (4.96 M) | ||||
| Market Capitalization | 33.79 M | ||||
| Total Asset | 8.87 M | ||||
| Retained Earnings | (51.56 M) | ||||
| Working Capital | 6.8 M | ||||
About Lexaria Bioscience Performance
Evaluating Lexaria Bioscience's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lexaria Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lexaria Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (4.74) | (4.50) | |
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | 0.14 | 0.14 | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (0.89) | (0.94) |
Things to note about Lexaria Bioscience Corp performance evaluation
Checking the ongoing alerts about Lexaria Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lexaria Bioscience Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lexaria Bioscience generated a negative expected return over the last 90 days | |
| Lexaria Bioscience has high historical volatility and very poor performance | |
| Lexaria Bioscience has some characteristics of a very speculative penny stock | |
| Lexaria Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 464.28 K. Net Loss for the year was (5.81 M) with profit before overhead, payroll, taxes, and interest of 494.2 K. | |
| Lexaria Bioscience Corp has accumulated about 1.31 M in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: Lexarias DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lillys Injectable Zepbound |
- Analyzing Lexaria Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lexaria Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Lexaria Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lexaria Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lexaria Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lexaria Bioscience's stock. These opinions can provide insight into Lexaria Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.